Pharmacological Therapy of Osteoporosis: What’s New?

Giovanni Iolascon,1 Antimo Moretti,1 Giuseppe Toro,1 Francesca Gimigliano,2 Sara Liguori,1 Marco Paoletta1 1Department of Medical and Surgical Specialties and Dentistry, University of Campania “Luigi Vanvitelli”, Naples, Italy; 2Department of Physical and Mental Health and Preven...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Iolascon G, Moretti A, Toro G, Gimigliano F, Liguori S, Paoletta M
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2020
Materias:	osteoporosis sequential therapy antiresorptive drugs bone anabolic drugs abaloparatide romosozumab Geriatrics RC952-954.6
Acceso en línea:	https://doaj.org/article/eb227d0a591949e9b37547517b7ed9c1
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:eb227d0a591949e9b37547517b7ed9c1
record_format	dspace
spelling	oai:doaj.org-article:eb227d0a591949e9b37547517b7ed9c12021-12-02T09:19:05ZPharmacological Therapy of Osteoporosis: What’s New?1178-1998https://doaj.org/article/eb227d0a591949e9b37547517b7ed9c12020-03-01T00:00:00Zhttps://www.dovepress.com/pharmacological-therapy-of-osteoporosis-whatrsquos-new-peer-reviewed-article-CIAhttps://doaj.org/toc/1178-1998Giovanni Iolascon,1 Antimo Moretti,1 Giuseppe Toro,1 Francesca Gimigliano,2 Sara Liguori,1 Marco Paoletta1 1Department of Medical and Surgical Specialties and Dentistry, University of Campania “Luigi Vanvitelli”, Naples, Italy; 2Department of Physical and Mental Health and Preventive Medicine, University of Campania “Luigi Vanvitelli”, Naples, ItalyCorrespondence: Antimo MorettiDepartment of Medical and Surgical Specialties and Dentistry, University of Campania “Luigi Vanvitelli”, Naples, ItalyEmail antimomor.83@hotmail.itAbstract: Osteoporosis and fragility fractures are relevant health issues because of their impact in terms of morbidity, mortality, and socioeconomic burden. Despite this alarming scenario, both underdiagnosis and undertreatment are common features of osteoporotic patients, particularly those who have already sustained a fragility fracture. Pharmacotherapy of osteoporosis is the main treatment option for these patients because of strong evidence about the efficacy of available drugs targeting bone metabolism. However, several issues can interfere with the effectiveness of anti-osteoporotic drugs in clinical practice, such as lack of awareness of both healthcare providers and patients, poor adherence to therapy, and safety in long-term treatment. Therefore, new therapeutic strategies have been proposed to overcome these problems, such as sequential therapy or emerging molecules mainly targeting the stimulation of bone formation. In particular, abaloparatide has been demonstrated to reduce major nonvertebral fracture risk compared with both placebo and teriparatide, although the European Medicines Agency (EMA) refused the marketing authorization because the benefits of this drug did not outweigh its risks. On the other side, EMA has recently approved romosozumab, a monoclonal antibody directed against sclerostin and the only available therapeutic option targeting Wnt signaling, as both bone-forming and antiresorptive intervention to treat osteoporosis and fragility fractures.Keywords: osteoporosis, sequential therapy, antiresorptive drugs, bone anabolic drugs, abaloparatide, romosozumabIolascon GMoretti AToro GGimigliano FLiguori SPaoletta MDove Medical Pressarticleosteoporosissequential therapyantiresorptive drugsbone anabolic drugsabaloparatideromosozumabGeriatricsRC952-954.6ENClinical Interventions in Aging, Vol Volume 15, Pp 485-491 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	osteoporosis sequential therapy antiresorptive drugs bone anabolic drugs abaloparatide romosozumab Geriatrics RC952-954.6
spellingShingle	osteoporosis sequential therapy antiresorptive drugs bone anabolic drugs abaloparatide romosozumab Geriatrics RC952-954.6 Iolascon G Moretti A Toro G Gimigliano F Liguori S Paoletta M Pharmacological Therapy of Osteoporosis: What’s New?
description	Giovanni Iolascon,1 Antimo Moretti,1 Giuseppe Toro,1 Francesca Gimigliano,2 Sara Liguori,1 Marco Paoletta1 1Department of Medical and Surgical Specialties and Dentistry, University of Campania “Luigi Vanvitelli”, Naples, Italy; 2Department of Physical and Mental Health and Preventive Medicine, University of Campania “Luigi Vanvitelli”, Naples, ItalyCorrespondence: Antimo MorettiDepartment of Medical and Surgical Specialties and Dentistry, University of Campania “Luigi Vanvitelli”, Naples, ItalyEmail antimomor.83@hotmail.itAbstract: Osteoporosis and fragility fractures are relevant health issues because of their impact in terms of morbidity, mortality, and socioeconomic burden. Despite this alarming scenario, both underdiagnosis and undertreatment are common features of osteoporotic patients, particularly those who have already sustained a fragility fracture. Pharmacotherapy of osteoporosis is the main treatment option for these patients because of strong evidence about the efficacy of available drugs targeting bone metabolism. However, several issues can interfere with the effectiveness of anti-osteoporotic drugs in clinical practice, such as lack of awareness of both healthcare providers and patients, poor adherence to therapy, and safety in long-term treatment. Therefore, new therapeutic strategies have been proposed to overcome these problems, such as sequential therapy or emerging molecules mainly targeting the stimulation of bone formation. In particular, abaloparatide has been demonstrated to reduce major nonvertebral fracture risk compared with both placebo and teriparatide, although the European Medicines Agency (EMA) refused the marketing authorization because the benefits of this drug did not outweigh its risks. On the other side, EMA has recently approved romosozumab, a monoclonal antibody directed against sclerostin and the only available therapeutic option targeting Wnt signaling, as both bone-forming and antiresorptive intervention to treat osteoporosis and fragility fractures.Keywords: osteoporosis, sequential therapy, antiresorptive drugs, bone anabolic drugs, abaloparatide, romosozumab
format	article
author	Iolascon G Moretti A Toro G Gimigliano F Liguori S Paoletta M
author_facet	Iolascon G Moretti A Toro G Gimigliano F Liguori S Paoletta M
author_sort	Iolascon G
title	Pharmacological Therapy of Osteoporosis: What’s New?
title_short	Pharmacological Therapy of Osteoporosis: What’s New?
title_full	Pharmacological Therapy of Osteoporosis: What’s New?
title_fullStr	Pharmacological Therapy of Osteoporosis: What’s New?
title_full_unstemmed	Pharmacological Therapy of Osteoporosis: What’s New?
title_sort	pharmacological therapy of osteoporosis: what’s new?
publisher	Dove Medical Press
publishDate	2020
url	https://doaj.org/article/eb227d0a591949e9b37547517b7ed9c1
work_keys_str_mv	AT iolascong pharmacologicaltherapyofosteoporosiswhatrsquosnew AT morettia pharmacologicaltherapyofosteoporosiswhatrsquosnew AT torog pharmacologicaltherapyofosteoporosiswhatrsquosnew AT gimiglianof pharmacologicaltherapyofosteoporosiswhatrsquosnew AT liguoris pharmacologicaltherapyofosteoporosiswhatrsquosnew AT paolettam pharmacologicaltherapyofosteoporosiswhatrsquosnew
_version_	1718398157379862528

Pharmacological Therapy of Osteoporosis: What&rsquo;s New?

Ejemplares similares

Pharmacological Therapy of Osteoporosis: What’s New?